Kiniksa Pharmaceuticals International (KNSA) Other financing activities (2018 - 2026)

Kiniksa Pharmaceuticals International's Other financing activities history runs 9 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• Quarterly Other financing activities rose 100.91% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.0 million (up 167.47% YoY) and the FY2025 annual result came in at $40.8 million, up 136.25% from the prior year.
• Other financing activities was $6.4 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $8.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $16.3 million in Q3 2025 and bottomed at $510000.0 in Q1 2023.
• A 5-year average of $4.2 million and a median of $1.7 million in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities slumped 78.77% — and 2025, when it soared 1022.91%.
• Kiniksa Pharmaceuticals International's Other financing activities stood at $1.3 million in 2022, then declined by 25.81% to $957000.0 in 2023, then jumped by 184.22% to $2.7 million in 2024, then jumped by 215.29% to $8.6 million in 2025, then retreated by 25.5% to $6.4 million in 2026.
• Business Quant data shows KNSA's Other financing activities at $6.4 million in Q1 2026, $8.6 million in Q4 2025, and $16.3 million in Q3 2025.